Matriarch

Organoids are miniature, simplified versions of human organs grown in the lab from stem cells. Key in preclinical research, organoids currently heavily depend on Matrigel, a cancer derived murine hydrogel with three (3) significant down-sides: high batch-to-batch variability, contaminated with tumor factors and low structural integrity (the matrix ‘breaks-up’ over larger volumes). These flaws erode reproducibility, inflate costs of research and make Matrigel-grown organoids unsuitable for clinical applications. 

With Matriarch 3DY Hydrogel, Matriarch Life Sciences not only addresses existing issues with the traditional hydrogels (such as Matrigel), but also provides the next level solution to the growing organoids market. With a batch-to-batch consistency and a tumor-factor-free composition, it is a research-grade Extra Cellular Matrix (ECM) derived hydrogel from sustainably sourced decellularized fetal yak livers. It is produced at scale under GMP conditions in a specialized facility on the pristine Tibetan Plateau from our exclusive partner. Because it is formulated from tissue-specific ECM rather than mouse sarcoma extract, organoids experience physiologically tuned stiffness that human cells experience in vivo. This is allowing growth of more naturally formed and larger organoids.

A peer reviewed journal publication (Biomaterials 2022) and data from additional internal studies show more real-life growth characteristics and higher structural integrity (as described above) than those grown in the softer, more variable traditional hydrogels (such as Matrigel). The composition and manufacturing process of our Matriarch 3DY Hydrogel is protected by a pending patent. Matriarch Life Sciences, with its Matriarch 3DY Hydrogel, is well positioned to capture a substantial share of the rapidly expanding hydrogel market. Our team combines deep scientific expertise, strong business acumen, and is building long term relationships with the major organoids CROs in The Netherlands including HUB Organoids, in Utrecht, the Netherlands. Early validation of Matriarch 3DY Hydrogel has already been done in our respective laboratories in Rotterdam and Lanzhou. By uniting best-in-class hydrogel performance with targeted partnerships, Matriarch Life Sciences is set to reshape global standards in organoid research.